IntelliCap Oral Drug Delivery System Wins European Innovation Award
News Nov 20, 2014
The IntelliCap electronic oral drug delivery technology, created by medtech innovator Medimetrics, has won a prestigious European ‘High-Tech Innovation Award’ from Accenture, the global management consultancy.
As Medimetrics CEO Olaf Weiner explained: “We are delighted to win this award, in recognition of the unique capabilities of the technology behind our drug delivery systems. The use of IntelliCap will help deliver a revolution in healthcare which both saves costs and improves the outcomes for patients.”
The IntelliCap system was introduced into the market in 2011. An increasing number of pharma companies are using this powerful tool in the early-stage development and life cycle management of drugs. This unique, interactive device enables personalization of medications and treatments, empowering scientists to establish quickly the effective medication dose and delivery requirements. This reduces the risk of failure in expensive, late stage clinical trials, due to lack of safety or efficacy.
While the IntelliCap system is applied to speed the development of new products, the technology’s strength is its ability to enable the development of other pioneering products.
As Dr Weiner added: “The spirit of the award was to recognize the potential of the IntelliCap technology. Its ability to adapt and personalize during delivery will help usher in an era of smart pharmaceuticals to the benefit of patients.”
An early example is in the field of women’s health. LiGalli, a pioneering Dutch company led by Dr. Willem de Laat, is integrating the technology into a novel vaginal drug delivery system that enables new therapies.
In another example, IntelliCap technology creates a means of sampling and mapping content from the small intestine to identify its microbiological composition, in a non-invasive way. The mapping process will provide novel insights into how certain foods and also therapeutic agents might react in the gut and so affect our health.
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE